Biomanufacturing sector set to ‘boost its efficiency’
28 September 2018 | By Mike Stones
The next five years will see game-changing improvements made in upstream, downstream and continuous bioprocessing, predicts one industry specialist...
List view / Grid view
Antibiotics
Whitepaper: BIOshell™ IgG 1000 Å C4 UHPLC column for improved biomacromolecule separations
28 June 2018 | By Merck
Monoclonal antibodies (mAbs) are widely manufactured by many biopharmaceutical companies to treat a myriad of diseases ranging from Alzheimer’s disease, Parkinson’s disease, ulcerative colitis, and many types of cancers...
New compound as effective as FDA-approved drugs against life-threatening infections
20 June 2018 | By European Pharmaceutical Review
Researchers have identified a new compound that in preliminary testing has shown itself to be as effective as antibiotics approved by the FDA to treat life-threatening infections while also appearing to be less susceptible to bacterial resistance.
Oral antibiotics may raise risk of kidney stones
14 May 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Paediatric researchers have found that children and adults treated with some oral antibiotics have a significantly higher risk of developing kidney stones...
Antibiotic use increases risk of severe viral disease in mice
28 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Killing gut bacteria with drugs weakens immune response...
Scientists develop rapid test that determines antibiotic resistance
16 March 2018 | By European Pharmaceutical Review
Scientists in Germany have developed a test using electric fields and Raman spectroscopy to ascertain specific antibiotic resistance of pathogens and thus enable the prescription of effective treatment.
Antibiotics may impact cancer treatment efficacy
6 March 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Improper use of antibiotics may have an unintended consequence of hampering cancer treatments...
DNA microarrays and multidrug resistant bacteria
1 March 2018 | By Dr Payam Behzadi
In parallel with the use of a wide range of antibiotics for treating infectious diseases worldwide, antimicrobial resistance has significantly increased. For this reason, the application of an advanced pangenomic technique like DNA microarray can be an effective, rapid, accurate, sensitive, specific and flexible methodology for detecting, identifying and determining…
Old antibiotic compounds could become tomorrow’s life-saving drugs
7 February 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
Scientists and chemists are re-examining old compounds to see whether they could hold the key to a future drug to combat increasingly resistant bacteria...
Computational method provides a potential boon in fighting antibiotic resistance
22 January 2018 | By Dr Zara Kassam (European Pharmaceutical Review)
A team of computer scientists have developed an algorithm that can rapidly search massive databases to discover novel variants of known antibiotics...
UK and Russian researchers join forces against AMR
14 December 2017 | By European Pharmaceutical Review
Two of the key organisations in the UK and Russia leading efforts to combat the global problem of antimicrobial resistance (AMR) have announced a formal agreement to work together.
New research into old antibiotic unearths potential improved TB drug
6 December 2017 | By European Pharmaceutical Review
A study by the University of Warwick and the Francis Crick Institute has enabled a deeper understanding of the mechanism of action of antibiotic drug, D-cycloserine, which holds promise for future TB treatment.
Glatiramer acetate found to fight multi-resistant bacteria
23 November 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Glatiramer acetate, a drug used to treat multiple sclerosis, has been found to have an effect on drug-resistant bacteria...
Albendazole-antibiotic combination shortens therapy for parasitic diseases
24 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Researchers have found a way of reducing the treatment required for lymphatic filariasis and onchocerciasis from several weeks to seven days...
Polyphor launches the development of an inhaled antibiotic murepavadin
12 October 2017 | By Dr Zara Kassam (European Pharmaceutical Review)
Polyphor Ltd has announced €5m funding, in order to support and accelerate the development of an inhaled dosage form of murepavadin...
Follow: